Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)

StatusRecruiting
PhaseNot applicable
SponsorEchosens
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 31, 2026 → Dec 31, 2027
See other at-risk trials from Echosens

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2026 to Dec 31, 2027 Show 8 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Jan 15, 2026 to Apr 23, 2026
    • Primary endpoints: details revised at 2 of 2 entries
    • Study completion pushed from Jan 15, 2027 to Jan 15, 2028
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 7 of 8 entries
    • Study description revised
    • Site details revised at 7 of 7 sites
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Echosens
4 trials monitored
See 3 trials at risk
Heart Disease
8,814 trials monitored
See 428 trials at risk
Heart Failure
2,000 trials monitored
See 115 trials at risk
This is a pivotal, global, prospective, cross-sectional, multicentric clinical investigation designed to explore a non-invasive, reliable alternative to invasive, catheter-based hemodynamic assessments, which are associated with procedural risks and limited applicability in certain participant populations.
Trial Details
NCT Number NCT07222813
Lead Sponsor Echosens
Collaborators: Syneos Health
Conditions
(from sponsor)		 Heart Failure, Heart Failure - NYHA II - IV
Related terms Heart Failure
Enrollment 149 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov